论文部分内容阅读
目的研究COMPASS三维剂量验证系统在鼻咽癌调强剂量验证中的应用。方法 10例鼻咽癌患者,其中男性8例,女性2例;年龄37~52岁,平均年龄43岁。利用COMPASS对全部病例的调强计划进行剂量验证,比较计划系统计算结果与COMPASS实际测量结果差异的主要指标,评价靶区V95%、Dmean,腮腺Dmean,脑干、脊髓、晶状体、视神经、视交叉的D1%及各自的γ通过率。结果各靶区V95%和Dmean的差异在3%、2%以内,GTV的差异最小,为-0.97%±0.46%、-0.68%±0.24%。靶区γ通过率多在95%左右。危及器官中脊髓、脑干D1%的差异分别为4.25%±1.37%、5.50%±1.60%。晶状体、视神经、视交叉D1%的差异在2%以内。腮腺Dmean的差异在6%以内。各危及器官的γ通过率均在98%以上。结论 COMPASS能够快速、直观地分析出鼻咽癌靶区和危及器官理论和实际照射情况下的剂量差异。
Objective To study the application of COMPASS three-dimensional dose verification system in dose enhancement of NPC. Methods 10 cases of nasopharyngeal carcinoma patients, including 8 males and 2 females; aged 37 to 52 years, mean age 43 years. COMPASS was used to dose-verify the intensity-modulation plan in all cases, and the main indicators of the difference between the calculated results of the planned system and those of COMPASS were compared. V95%, Dmean, Dmean, brain stem, spinal cord, lens, optic nerve, Of D1% and their respective γ-pass rates. Results The difference of V95% and Dmean in each target area was within 3% and 2%, and the difference of GTV was the lowest, -0.97% ± 0.46% and -0.68% ± 0.24%. The target γ pass rate of more than 95%. The differences of D1% in the spinal cord and brainstem in the endangering organs were 4.25% ± 1.37% and 5.50% ± 1.60% respectively. Lens, optic nerve, optic chiasm D1% difference within 2%. Parotid Dmean differences within 6%. The γ-passage rate of all the organs at risk is over 98%. Conclusion COMPASS can quickly and intuitively analyze the dosage differences between nasopharyngeal carcinoma target and endangered organs in theory and actual irradiation.